SecSonar.com

Syndax Pharmaceuticals, Inc. (SNDX)

Syndax Pharmaceuticals, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Syndax Pharmaceuticals, Inc. (SNDX) is a Biotechnology company based in US with a market capitalization of $1.7B. Free cash flow was negative at -$323.2M. This page tracks SNDX's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 270 employees · IPO Mar 2, 2016

Valuation

Valuation & price

$20.23 · as of May 17, 2026 · -19.6% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

27.01

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$25.15$16.94$8.73Jul 25Dec 25Jul 26Jul 7, 25$8.73Jul 9, 25$9.24Jul 11, 25$9.59Jul 15, 25$9.21Jul 17, 25$9.67Jul 21, 25$9.73Jul 23, 25$10.22Jul 25, 25$9.63Jul 29, 25$10.35Jul 31, 25$9.92Aug 4, 25$10.38Aug 6, 25$12.89Aug 11, 25$12.51Aug 13, 25$13.45Aug 15, 25$15.74Aug 19, 25$15.40Aug 21, 25$15.84Aug 25, 25$15.66Aug 27, 25$16.26Aug 29, 25$16.33Sep 3, 25$16.13Sep 5, 25$17.04Sep 9, 25$15.93Sep 11, 25$16.37Sep 16, 25$15.04Sep 18, 25$15.45Sep 22, 25$14.89Sep 24, 25$15.01Sep 26, 25$15.68Sep 30, 25$15.39Oct 2, 25$15.44Oct 6, 25$16.40Oct 8, 25$16.50Oct 10, 25$16.06Oct 14, 25$15.31Oct 16, 25$15.05Oct 21, 25$15.20Oct 23, 25$14.68Oct 27, 25$13.11Oct 29, 25$13.22Oct 31, 25$13.70Nov 4, 25$15.35Nov 6, 25$14.69Nov 10, 25$15.72Nov 12, 25$16.79Nov 14, 25$16.62Nov 18, 25$17.09Nov 20, 25$17.05Nov 25, 25$19.45Nov 28, 25$19.82Dec 2, 25$18.79Dec 4, 25$19.74Dec 8, 25$19.98Dec 10, 25$20.62Dec 12, 25$20.37Dec 16, 25$20.72Dec 18, 25$20.23Dec 22, 25$21.48Dec 24, 25$21.60Dec 29, 25$21.07Jan 2, 26$21.30Jan 6, 26$20.34Jan 8, 26$21.39Jan 12, 26$20.72Jan 14, 26$21.44Jan 16, 26$20.52Jan 21, 26$20.52Jan 23, 26$20.25Jan 27, 26$21.31Jan 29, 26$20.59Feb 2, 26$21.35Feb 4, 26$20.43Feb 9, 26$21.19Feb 11, 26$21.71Feb 13, 26$20.48Feb 18, 26$20.25Feb 20, 26$19.69Feb 24, 26$20.53Feb 26, 26$20.67Mar 2, 26$22.14Mar 4, 26$21.62Mar 6, 26$22.07Mar 10, 26$24.16Mar 12, 26$23.99Mar 17, 26$23.77Mar 19, 26$24.00Mar 23, 26$24.09Mar 25, 26$24.20Mar 27, 26$23.49Mar 31, 26$23.36Apr 2, 26$25.15Apr 7, 26$24.64Apr 9, 26$24.76Apr 13, 26$24.25Apr 15, 26$24.33Apr 17, 26$24.23Apr 22, 26$22.08Apr 24, 26$21.39Apr 28, 26$21.11Apr 30, 26$21.43May 4, 26$19.96May 6, 26$20.65May 8, 26$21.49May 12, 26$20.41May 14, 26$20.55May 18, 26$19.41May 20, 26$20.13May 22, 26$19.94May 28, 26$19.75Jun 1, 26$18.85Jun 3, 26$18.34Jun 5, 26$17.34Jun 9, 26$17.69Jun 11, 26$17.91Jun 15, 26$18.48Jun 17, 26$19.04Jun 22, 26$19.32Jun 24, 26$19.98Jun 26, 26$21.31Jul 2, 26$21.38
$8.7352-week range$25.15
Loading valuation history…

Fundamentals

Key fundamentals

$1.7B

Market cap

—

Revenue growth (YoY)

96.0%

Gross margin

-$323.2M

Free cash flow (USD)

-$47.6M

Net debt

Net cash position

1.2%

Share dilution

0/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$1.2MFY 2017$2.1MFY 2018$1.5MFY 2019$1.5MFY 2020$1.5MFY 2021$139.7MFY 2022$0.00FY 2023$0.00FY 2024$23.7MFY 2025$172.4M
$1.2M$172.4M

Free cash flow by year

2016 → 2025

FY 2016$-35.4MFY 2017$-47.5MFY 2018$-68.7MFY 2019$-50.6MFY 2020$-71.3MFY 2021$29.0MFY 2022$-133.9MFY 2023$-160.6MFY 2024$-274.9MFY 2025$-323.2M
-$35.4M-$323.2M

Gross margin by year

2021 → 2025

FY 2021100.0%FY 202496.5%FY 202596.0%
100.0%96.0%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

3

Insider sells · 90 days

Earnings

Last report: 10-Q filed Apr 30, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • Insider sellInsider Sell $1.2M · 10b5-1 PlanBotwood Nicholas A.J. · Head of R&D, CMO · $1.2MJun 12, 2026Filing
  • 8-K eventEquity Incentive Plan AdoptedJun 10, 2026Filing
  • 8-K eventConvertible Notes IssuedJun 10, 2026Filing
  • 8-K eventConvertible Notes OfferingJun 4, 2026Filing
  • Insider sellInsider Sell $130KMetzger Michael A · Director, Chief Executive Officer · $130KJun 2, 2026Filing
  • Insider sellInsider Sell $22KGoldan Keith A. · Chief Financial Officer · $22.4KJun 2, 2026Filing
  • 8-K eventEarnings ReleaseApr 30, 2026Filing
  • Quarterly report10-Q FiledApr 30, 2026Filing

Questions

Frequently asked questions

What is Syndax Pharmaceuticals, Inc.'s market cap?

Syndax Pharmaceuticals, Inc. (SNDX) has a market capitalization of $1.7B.

What is SNDX's P/E ratio?

A meaningful P/E ratio is not available for SNDX — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is SNDX's price-to-book (P/B) ratio?

SNDX trades at 27.01 times book value per share.

Are insiders buying SNDX stock?

SEC Form 4 filings show no open-market insider buys at Syndax Pharmaceuticals, Inc. in the last 90 days (3 sells).

Same arena

Related companies in Biotechnology

VCEL

Vericel Corporation

$1.7B

AGIO

Agios Pharmaceuticals, Inc.

$1.8B

NVAX

Novavax, Inc.

$1.8B

ATAI

Atai Beckley N.V

$1.7B

HRMY

Harmony Biosciences Holdings, Inc.

$1.8B

OCS

Oculis Holding AG

$1.7B

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.